Cargando…
Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683105/ https://www.ncbi.nlm.nih.gov/pubmed/36438279 http://dx.doi.org/10.3389/fpubh.2022.1059495 |
| _version_ | 1784835000143708160 |
|---|---|
| author | Liu, Jia Cao, Lidan Wu, Jing |
| author_facet | Liu, Jia Cao, Lidan Wu, Jing |
| author_sort | Liu, Jia |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9683105 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96831052022-11-24 Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China Liu, Jia Cao, Lidan Wu, Jing Front Public Health Public Health Frontiers Media S.A. 2022-11-09 /pmc/articles/PMC9683105/ /pubmed/36438279 http://dx.doi.org/10.3389/fpubh.2022.1059495 Text en Copyright © 2022 Liu, Cao and Wu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Public Health Liu, Jia Cao, Lidan Wu, Jing Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China |
| title | Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China |
| title_full | Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China |
| title_fullStr | Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China |
| title_full_unstemmed | Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China |
| title_short | Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China |
| title_sort | corrigendum: cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in china |
| topic | Public Health |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683105/ https://www.ncbi.nlm.nih.gov/pubmed/36438279 http://dx.doi.org/10.3389/fpubh.2022.1059495 |
| work_keys_str_mv | AT liujia corrigendumcostutilityanalysisoflurasidoneforthefirstlinetreatmentofschizophreniainchina AT caolidan corrigendumcostutilityanalysisoflurasidoneforthefirstlinetreatmentofschizophreniainchina AT wujing corrigendumcostutilityanalysisoflurasidoneforthefirstlinetreatmentofschizophreniainchina |